Rznomics, a clinical-stage South Korean biotech developing RNA-based gene therapies, is joining Lilly Gateway Labs — Eli Lilly’s innovation hub in San Diego — to accelerate its drug discovery and development.
Importantly, this is an incubator partnership, not an acquisition. Rznomics keeps its independence while gaining access to wet-lab facilities, Lilly scientists and executives, and support for candidate development, global clinical infrastructure, partnerships and US-based R&D hiring.
Why the distinction matters
The independence point is the substance of the arrangement rather than a legal footnote.
An acquired biotech loses control of its priorities. Programmes get reprioritised against the acquirer’s portfolio, decision-making slows, and the speed that made a small company attractive frequently disappears — a well-documented pattern in pharmaceutical acquisitions.
An incubator arrangement preserves that speed while supplying what a small company lacks. Rznomics continues setting its own direction and gains facilities and expertise it could not otherwise access.
What a small biotech actually needs
The listed benefits are more substantial than they sound, because each represents years of work and considerable capital.
Wet-lab facilities in a hub like San Diego are expensive and, until recently, scarce. Fitting out laboratory space requires specialised ventilation, utilities and safety systems, and a small company signing a long lease commits capital it would rather spend on science.
Global clinical infrastructure is the harder item. Running trials across multiple countries requires regulatory expertise per jurisdiction, site relationships, monitoring capability and data systems — capabilities a company with a few dozen employees cannot build and normally rents expensively from contract research organisations.
US-based R&D hiring matters for a Korean company specifically. Access to the US talent pool, and a physical US presence, changes what a company can recruit for and how credibly it can operate in its largest potential market.
What Rznomics brings
The company runs a target-gene database of more than 200 disease targets and works on RNA-based approaches to gene therapy.
“Joining Lilly Gateway Labs in San Diego represents a meaningful milestone for Rznomics’ proprietary RNA platform,” said CEO Seong-Wook Lee.
Why big pharma runs incubators
Lilly Gateway Labs is part of a broader Lilly Catalyze360 ecosystem offering biotech startups lab space, capital and expertise without taking them over.
The strategic logic is about optionality and information. A large pharmaceutical company cannot internally pursue every emerging modality, and the returns on trying are poor — internal programmes in unfamiliar technology tend to lag specialists.
Hosting companies working on those modalities provides something more valuable than a licence: proximity. Lilly gets a close view of how the platform performs, which problems it encounters and whether it works, long before that information becomes public. If it succeeds, Lilly is well positioned to partner or acquire, having watched the science develop. If it fails, Lilly has lost only facilities costs.
That is cheap optionality on a technology the company would otherwise have to bet on blind.
Why RNA therapeutics specifically
The deal reflects rising interest in RNA-based medicines beyond the vaccines that made the technology famous.
mRNA vaccines demonstrated that RNA could be manufactured at scale, delivered safely and produce a therapeutic effect — validating infrastructure and regulatory pathways in a way years of earlier work had not.
The therapeutic applications are broader and harder. Vaccines need only deliver RNA to some cells, briefly, to prompt an immune response. A therapy must reach a specific tissue, produce a sustained effect, and be re-dosed indefinitely — a considerably more demanding proposition, and one where delivery remains the central unsolved problem.
The realistic read
For Rznomics this is genuine access to capability, not merely a prestigious address — and for a Korean company seeking to operate in the US, the infrastructure is worth more than the branding.
Korea’s biotech sector is looking outward
The nationality of the partner is not incidental, and it fits a pattern visible across recent dealmaking.
South Korean biotechs have become frequent partners for Western pharmaceutical companies, appearing in licensing deals across oncology, obesity and immunology. The country has built substantial capability in protein engineering, antibody development and manufacturing, supported by sustained government investment and a strong domestic industrial base.
What those companies have generally lacked is the infrastructure for global development and commercialisation — which is expensive, requires jurisdiction-specific expertise, and is difficult to build from a domestic market of modest size.
The resulting arrangement is consistent: the Korean company generates the asset or platform and retains its home market, while a Western partner takes global rights and handles development. An incubator place is a lighter version of the same trade — access to infrastructure without giving up the asset, which is a better deal for the originator if the platform proves out.
For Lilly it is a low-cost position in a modality it wants visibility on. Neither party has committed to anything beyond the arrangement itself, which is precisely what makes it attractive to both. Business news, not investment advice.